References

  1. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with highly active antiretroviral therapy on cardiovascular risk and life expectancy. Am J Cardiol. 2005 Mar 1;95(5):586-91. This article on PubMed

  2. Kasper LD, Braunwald ES, Fauci SA, Hauser SL, Longo DL, Jameson LJ. Harrison's Principles of Internal Medicine- 17 th edition. 2008. New York. McGraw-Hill Medical Publishing Division.

  3. Guardiola M, Ferré R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, Masana L, Ribalta J. Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5-1131T3C Gene Variation.Clin Chem. 2006 Oct;52(10):1914-9. This article on PubMed

  4. Clotet B, Negredo E. HIV Protease Inhibitors and Dyslipidemia. AIDS Rev. 2003; 5:19-24. This article on PubMed

  5. Wu PY, Hung CC, Liu WC, Hsieh CY, Sun HY, Lu CL, Wu H, Chien KL. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother. 2012; 67(4):1001-1009. This article on PubMed

  6. Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodriguez J, Vázquez G. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor. Antivir Ther. 2003; 8(3):223-231. This article on PubMed

  7. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53(1):10-14. This article on PubMed

  8. Barbaro G, Iacobellis G. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep. 2009; 9(1):37-42. This article on PubMed

  9. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109:433- 438. This article on PubMed

  10. National Institutes of Health. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed September 2011.

  11. Milinkovic A. HIV-Associated Lipodystrophy Syndrome.Coll Antropol. 2006 Dec;30 Suppl 2:59-62. This article on PubMed

  12. Gardner D, Shoback D. Greenspan's Basic; Clinical Endocrinology-8th edition.2007.New York. McGraw-Hill

  13. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2008; 31 (Suppl 1): S12-54. This article on PubMed

  14. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet. 1999 Jun 19;353(9170):2093-9. This article on PubMed

  15. Kravcik S. HIV lipodystrophy: a review. HIV Clin Trials. 2000;1(3):37-50. This article on PubMed

  16. Balasubramanyam A, Sekhar RV. HIV-associated lipodystrophy syndrome: an accelerated form of the metabolic syndrome of insulin resistance due to altered fat distribution. Res Initiat Treat Action. 2006; 12(1):5-11. This article on PubMed

  17. Estrada V, Martínez-Larrad MT, González-Sánchez JL, de Villar NG, Zabena C, Fernández C, Serrano-Ríos M. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral Therapy. Metabolism. 2006; 55(7):940-945. This article on PubMed

  18. Macallan DC. Metabolic syndromes in human immunodeficiency virus infection. Horm Res. 2001; 55 (Suppl 1):36-41. This article on PubMed

  19. Manuthu EM, Joshi MD, Lule GN, Karari E. Prevalence of Dyslipidemia and Dysgycaemia in HIV Infected Patients. East Afr Med J. 2008;85(1):10-7. This article on PubMed

  20. Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, Cordier L, Pusterla L, Bombelli M, Sega R, Quirino T, Mancia G. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr. 2007; 45(4):426-31. This article on PubMed

  21. Squillace N,Orlando G, Roverato A, Stentarelli C, Zona S, Nardini G, Beghetto B, Esposito R, Guaraldi G. Metabolic syndrome in HIV- associated lipodystrophy. HAART and correlated pathologies. 2008; 1: 35-38.

  22. Kalyanasundaram AP, Mini SJacob, Hemalatha R, Rajappa MS. Prevalence of Lipodystrophy and Dyslipidemia among Patients with HIV Infection on Generic ART in Rural South India. JIAPAC. 2012;11(5): 329-334. This article on PubMed

  23. Ramezani A, Mohraz M, Yadegarinia D, Banifazl M, Gachkar L, Jam S, Aghakhani A, Eslamifar A, Yaghmaie F, Nemati K, Akbar AV. Prevalence of Dyslipidemia and Metabolic Abnormalities in HIV-Infected Patients. Acta Medica Iranica. 2009; 47(2): 83-88.